William Blair Forecasts argenex’s Q3 Earnings (NASDAQ:ARGX)

argenex SE (NASDAQ:ARGX) – Research analysts at William Blair boosted their Q3 2025 earnings estimates for argenex in a research report issued to clients and investors on Friday, October 10th. William Blair analyst M. Minter now anticipates that the company will earn $4.60 per share for the quarter, up from their previous estimate of $4.57. The consensus estimate for argenex’s current full-year earnings is $3.13 per share.

Several other research firms have also recently issued reports on ARGX. Wells Fargo & Company increased their price target on argenex from $741.00 to $756.00 and gave the stock an “overweight” rating in a research note on Thursday, July 31st. Guggenheim reiterated a “buy” rating and issued a $1,070.00 target price on shares of argenex in a research report on Thursday, September 18th. Truist Financial boosted their price target on shares of argenex from $700.00 to $918.00 and gave the stock a “buy” rating in a research report on Monday, September 15th. Piper Sandler increased their price objective on shares of argenex from $750.00 to $820.00 and gave the company an “overweight” rating in a report on Tuesday, August 26th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of argenex in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, argenex has an average rating of “Buy” and a consensus target price of $817.53.

argenex Trading Up 0.3%

Shares of NASDAQ ARGX opened at $799.56 on Monday. argenex has a 12-month low of $510.05 and a 12-month high of $810.16. The company has a market cap of $48.93 billion, a PE ratio of 41.00, a P/E/G ratio of 0.86 and a beta of 0.46. The stock has a 50 day simple moving average of $722.14 and a 200-day simple moving average of $629.47.

argenex (NASDAQ:ARGX) last posted its earnings results on Thursday, July 31st. The company reported $3.74 EPS for the quarter, topping the consensus estimate of $2.84 by $0.90. The firm had revenue of $866.79 million during the quarter, compared to analysts’ expectations of $776.82 million. argenex had a net margin of 40.98% and a return on equity of 21.06%.

Institutional Investors Weigh In On argenex

Several hedge funds have recently modified their holdings of ARGX. Rakuten Securities Inc. boosted its position in shares of argenex by 56.4% in the 1st quarter. Rakuten Securities Inc. now owns 61 shares of the company’s stock valued at $36,000 after purchasing an additional 22 shares during the period. WPG Advisers LLC purchased a new stake in argenex during the first quarter valued at about $37,000. Golden State Wealth Management LLC acquired a new position in shares of argenex in the first quarter worth about $44,000. Brooklyn Investment Group boosted its holdings in shares of argenex by 102.7% in the first quarter. Brooklyn Investment Group now owns 75 shares of the company’s stock worth $44,000 after buying an additional 38 shares during the period. Finally, MAI Capital Management increased its position in shares of argenex by 866.7% in the second quarter. MAI Capital Management now owns 87 shares of the company’s stock worth $48,000 after acquiring an additional 78 shares in the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.